Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

Daniel J. George; Colin Hessel; Susan Halabi; M. Dror Michaelson; Olwen Hahn; Meghara Walsh; Joel Picus; Eric J. Small; Shaker Dakhil; Darren R. Feldman; Milan Mangeshkar; Christian Scheffold; Michael J. Morris; Toni K. Choueiri

doi:10.1634/theoncologist.2019-0316

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

Daniel J. George
, Colin Hessel
, Susan Halabi
, M. Dror Michaelson
, Olwen Hahn
, Meghara Walsh
, Joel Picus
, Eric J. Small
, Shaker Dakhil
, Darren R. Feldman
, Milan Mangeshkar
, Christian Scheffold
, Michael J. Morris
, Toni K. Choueiri

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.

Original language	English
Pages (from-to)	1497-1501
Number of pages	5
Journal	Oncologist
Volume	24
Issue number	11
DOIs	https://doi.org/10.1634/theoncologist.2019-0316
State	Published - Nov 1 2019

Access to Document

10.1634/theoncologist.2019-0316

Cite this

George, D. J., Hessel, C., Halabi, S., Michaelson, M. D., Hahn, O., Walsh, M., Picus, J., Small, E. J., Dakhil, S., Feldman, D. R., Mangeshkar, M., Scheffold, C., Morris, M. J., & Choueiri, T. K. (2019). Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist, 24(11), 1497-1501. https://doi.org/10.1634/theoncologist.2019-0316

@article{654a70140fef4893b753ea56cff08404,

title = "Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial",

abstract = "Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.",

author = "George, \{Daniel J.\} and Colin Hessel and Susan Halabi and Michaelson, \{M. Dror\} and Olwen Hahn and Meghara Walsh and Joel Picus and Small, \{Eric J.\} and Shaker Dakhil and Feldman, \{Darren R.\} and Milan Mangeshkar and Christian Scheffold and Morris, \{Michael J.\} and Choueiri, \{Toni K.\}",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.",

year = "2019",

month = nov,

day = "1",

doi = "10.1634/theoncologist.2019-0316",

language = "English",

volume = "24",

pages = "1497--1501",

journal = "Oncologist",

issn = "1083-7159",

number = "11",

}

George, DJ, Hessel, C, Halabi, S, Michaelson, MD, Hahn, O, Walsh, M, Picus, J, Small, EJ, Dakhil, S, Feldman, DR, Mangeshkar, M, Scheffold, C, Morris, MJ & Choueiri, TK 2019, 'Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial', Oncologist, vol. 24, no. 11, pp. 1497-1501. https://doi.org/10.1634/theoncologist.2019-0316

TY - JOUR

T1 - Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk

T2 - Subgroup Analysis of the Alliance A031203 CABOSUN trial

AU - George, Daniel J.

AU - Hessel, Colin

AU - Halabi, Susan

AU - Michaelson, M. Dror

AU - Hahn, Olwen

AU - Walsh, Meghara

AU - Picus, Joel

AU - Small, Eric J.

AU - Dakhil, Shaker

AU - Feldman, Darren R.

AU - Mangeshkar, Milan

AU - Scheffold, Christian

AU - Morris, Michael J.

AU - Choueiri, Toni K.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.

AB - Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.

UR - https://www.scopus.com/pages/publications/85070453089

U2 - 10.1634/theoncologist.2019-0316

DO - 10.1634/theoncologist.2019-0316

M3 - Article

C2 - 31399500

AN - SCOPUS:85070453089

SN - 1083-7159

VL - 24

SP - 1497

EP - 1501

JO - Oncologist

JF - Oncologist

IS - 11

ER -

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

Abstract

Access to Document

Other files and links

Fingerprint

Cite this